Semaglutide

Most common during dose escalation, typically resolves within 1-2 weeks as the body adapts. Occurs in 25-40% of users. Manage by eating smaller, frequent meals; avoiding fatty or greasy foods; and staying hydrated. Usually diminishes with continued use.

Occurs in 5-10% of users, usually during initial titration or after dose increases. Typically self-resolving within days. If persistent, contact healthcare provider.

Reported in 20-30% of users, often during dose escalation. Usually mild and transient. Manage with adequate hydration and dietary adjustments (increase fiber gradually, avoid high-fat foods). Typically resolves within 1-2 weeks.

Occurs in 15-25% of users. Manage by increasing water intake, consuming adequate dietary fiber, and light physical activity. May alternate with diarrhea during dose titration.

Reported in 5-15% of users, usually mild and transient. Often related to gastrointestinal changes. Manage with small, frequent meals and over-the-counter antacids if needed.

Mild erythema, bruising, or discomfort at injection site occurs in 1-5% of users. Minimize by rotating injection sites, using proper injection technique, and allowing solution to reach room temperature before injection.

Reported in 5-10% of users. Usually mild and self-resolving. May be related to dehydration or rapid blood glucose changes.

Occurs in 5-10% of users, typically during initial titration. Usually resolves as the body adapts. Ensure adequate caloric intake and hydration.

This is an intended pharmacological effect for weight management but can be pronounced during dose escalation. Ensure adequate nutrient intake despite reduced appetite. Eat nutrient-dense foods in smaller portions.

Risk is low when semaglutide is used alone due to glucose-dependent insulin secretion. Risk increases significantly if combined with other diabetes medications (sulfonylureas, insulin). Monitor blood glucose if on combination therapy. Symptoms: shakiness, sweating, confusion, rapid heartbeat. Treat with 15g fast-acting carbohydrate.

Rare but serious adverse event reported in <0.1% of users. Symptoms: severe upper abdominal pain, back pain, vomiting, elevated pancreatic enzymes. Seek immediate medical attention if suspected. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Rapid weight loss increases gallstone risk. Reported in 1-3% of users with significant weight loss. Symptoms: right upper quadrant pain, nausea. Manage with gradual weight loss and adequate fat intake. Consult healthcare provider if symptoms develop.

Can occur due to gastrointestinal side effects and reduced fluid intake from decreased appetite. Maintain consistent hydration, especially during dose escalation. Monitor for dizziness, dry mouth, or dark urine.

GLP-1 agonists caused C-cell hyperplasia and medullary thyroid carcinoma in rodent studies at high doses. Human relevance is unclear. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). Not recommended in patients with thyroid nodules or elevated calcitonin.

Rapid improvement in blood glucose control may temporarily worsen diabetic retinopathy in patients with pre-existing retinopathy. Ophthalmology monitoring recommended for patients with diabetic retinopathy. Risk is generally low with gradual dose titration.

Rare reports of acute kidney injury, often associated with severe dehydration and gastrointestinal side effects. Maintain adequate hydration. Monitor renal function, especially in patients with pre-existing kidney disease. Seek medical attention if urine output decreases or signs of kidney dysfunction appear.

Rare reports of hypersensitivity reactions including rash, angioedema, or anaphylaxis. Seek immediate medical attention if difficulty breathing, facial swelling, or severe rash develops. Discontinue use if allergic reaction suspected.